Meeting
2020 Genitourinary Cancers Symposium
PSA status after neoadjuvant androgen deprivation therapy before high-dose-rate brachytherapy as biomarker for prediction of long-term outcome in high-risk prostate cancer patients.
Authors
Trude Wedde
Oslo University Hospital, Oslo, Norway
Trude Wedde , Milada Cvancarova , Jonathan S. Hayman , Phuoc T. Tran , Gunnar Tafjord , Theodore L. DeWeese , Wolfgang Lilleby
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 301)
Abstract #
301
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Planned interim analysis of perioperative safety of fluzoparib combined with abiraterone in the neoadjuvant treatment of locoregional high-risk prostate cancer: Results from multicenter, phase 2 FAST-PC trial.
First Author: Yao Zhu
Poster
2021 Genitourinary Cancers Symposium
Preoperative predictors of biochemical recurrence in a phase II trial of neoadjuvant therapy in very high-risk prostate cancer.
First Author: Ashanda Rosetta Patrice Esdaille
Poster
2019 Genitourinary Cancers Symposium
External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar
Poster
2019 Genitourinary Cancers Symposium
A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).
First Author: Fatima Karzai